B-control	0	4	High
I-control	4	5	-
I-control	5	9	dose
I-control	10	14	oral
I-control	15	34	medroxyprogesterone
I-control	35	42	acetate
O	43	45	or
B-intervention	46	55	tamoxifen
O	56	58	as
O	59	67	adjuvant
O	68	75	hormone
O	76	83	therapy
O	84	87	for
O	88	92	node
O	92	93	-
O	93	101	negative
O	102	107	early
O	107	108	-
O	108	113	stage
O	114	120	breast
O	121	127	cancer
O	127	128	:
O	129	139	randomized
O	140	145	trial
O	146	150	with
O	151	152	7
O	152	153	-
O	153	157	year
O	158	164	update
O	164	165	.

O	166	167	A
O	168	178	randomized
O	179	187	adjuvant
O	188	193	trial
O	194	202	compared
O	203	212	tamoxifen
O	213	215	20
O	216	218	mg
O	219	224	daily
O	225	228	for
O	229	230	5
O	231	236	years
O	237	241	with
O	242	246	high
O	246	247	-
O	247	251	dose
O	252	256	oral
O	257	276	medroxyprogesterone
O	277	284	acetate
O	285	286	(
O	286	289	MPA
O	289	290	)
O	291	292	1
O	293	294	g
O	295	301	orally
O	302	305	for
O	306	307	9
O	308	314	months
O	314	315	.

B-total-participants	316	319	One
I-total-participants	320	327	hundred
I-total-participants	328	334	ninety
I-total-participants	334	335	-
I-total-participants	335	339	four
B-eligibility	340	348	patients
I-eligibility	349	353	with
I-eligibility	354	368	histologically
I-eligibility	369	375	proven
I-eligibility	376	383	primary
I-eligibility	384	388	node
I-eligibility	388	389	-
I-eligibility	389	397	negative
I-eligibility	398	404	breast
I-eligibility	405	414	carcinoma
O	415	419	were
O	420	428	enrolled
O	429	436	between
O	437	445	December
O	446	450	1990
O	451	454	and
O	455	462	October
O	463	467	1996
O	467	468	,
O	469	473	with
B-intervention-participants	474	476	98
O	477	485	patients
O	486	496	randomized
O	497	501	into
O	502	505	the
O	506	515	tamoxifen
O	516	519	arm
O	520	523	and
B-control-participants	524	526	96
O	527	531	into
O	532	535	the
O	536	539	MPA
O	540	543	arm
O	543	544	.

O	545	547	At
O	548	549	a
O	550	556	median
O	557	563	follow
O	563	564	-
O	564	566	up
O	567	569	of
O	570	572	86
O	573	579	months
O	579	580	,
O	581	583	25
B-outcome	584	592	relapses
O	593	596	and
O	597	599	13
B-outcome	600	606	deaths
O	607	611	were
O	612	620	recorded
O	620	621	.

O	622	625	The
B-outcome	626	633	relapse
I-outcome	633	634	-
I-outcome	634	638	free
I-outcome	639	647	survival
I-outcome	648	652	rate
I-outcome	653	655	at
I-outcome	656	657	7
I-outcome	658	663	years
O	664	666	in
O	667	670	the
O	671	680	tamoxifen
O	681	684	arm
O	685	688	was
B-iv-bin-percent	689	691	93
I-iv-bin-percent	691	692	%
O	692	693	,
O	694	700	versus
B-cv-bin-percent	701	703	81
I-cv-bin-percent	703	704	%
O	705	707	in
O	708	711	the
O	712	715	MPA
O	716	719	arm
O	720	721	(
O	721	722	P
O	723	724	=
O	725	726	0
O	726	727	.
O	727	729	02
O	729	730	)
O	730	731	.

O	732	735	The
O	736	746	difference
O	747	750	was
O	751	759	observed
O	760	762	in
O	763	771	patients
O	772	776	with
B-outcome	777	782	stage
I-outcome	783	785	T2
I-outcome	786	793	disease
O	794	795	(
B-iv-bin-percent	795	798	100
I-iv-bin-percent	798	799	%
O	800	802	in
O	803	806	the
O	807	816	tamoxifen
O	817	822	group
O	823	825	vs
O	825	826	.
B-cv-bin-percent	827	829	64
I-cv-bin-percent	829	830	%
O	831	833	in
O	834	837	the
O	838	841	MPA
O	842	847	group
O	847	848	;
O	849	850	P
O	851	852	=
O	853	854	0
O	854	855	.
O	855	857	01
O	857	858	)
O	858	859	,
O	860	862	in
B-outcome	863	870	younger
I-outcome	871	874	and
I-outcome	874	875	/
I-outcome	875	877	or
I-outcome	878	891	premenopausal
I-outcome	892	900	patients
O	901	902	(
O	902	904	in
O	905	913	patients
O	914	915	<
O	916	918	50
O	919	924	years
O	925	927	of
O	928	931	age
O	931	932	,
B-iv-bin-percent	933	936	100
I-iv-bin-percent	936	937	%
O	938	940	in
O	941	944	the
O	945	954	tamoxifen
O	955	958	arm
O	959	961	vs
O	961	962	.
B-cv-bin-percent	963	965	81
I-cv-bin-percent	965	966	%
O	967	969	in
O	970	973	the
O	974	977	MPA
O	978	981	arm
O	982	983	[
O	983	984	P
O	985	986	=
O	987	988	0
O	988	989	.
O	989	991	02
O	991	992	]
O	992	993	,
O	994	997	and
O	998	1000	in
B-outcome	1001	1009	patients
I-outcome	1010	1011	>
I-outcome	1012	1014	or
I-outcome	1015	1016	=
I-outcome	1017	1019	50
I-outcome	1020	1025	years
I-outcome	1026	1028	of
I-outcome	1029	1032	age
O	1032	1033	,
B-iv-bin-percent	1034	1036	90
I-iv-bin-percent	1036	1037	%
O	1038	1040	in
O	1041	1044	the
O	1045	1054	tamoxifen
O	1055	1058	arm
O	1059	1061	vs
O	1061	1062	.
B-cv-bin-percent	1063	1065	82
I-cv-bin-percent	1065	1066	%
O	1067	1069	in
O	1070	1073	the
O	1074	1077	MPA
O	1078	1081	arm
O	1082	1083	[
O	1083	1084	P
O	1085	1086	=
O	1087	1088	0
O	1088	1089	.
O	1089	1091	16
O	1091	1092	]
O	1092	1093	)
O	1093	1094	.

O	1095	1099	Also
O	1099	1100	,
O	1101	1104	the
B-outcome	1105	1112	overall
I-outcome	1113	1121	survival
I-outcome	1122	1126	rate
I-outcome	1127	1129	at
I-outcome	1130	1131	7
I-outcome	1132	1137	years
O	1138	1141	was
O	1142	1147	lower
O	1148	1150	in
O	1151	1156	women
O	1157	1158	<
O	1159	1161	50
O	1162	1167	years
O	1168	1170	of
O	1171	1174	age
O	1175	1176	(
O	1176	1177	P
O	1178	1179	=
O	1180	1181	0
O	1181	1182	.
O	1182	1184	04
O	1184	1185	)
O	1185	1186	.
